Class of Stock [Axis]
Common Stock, $0.001 par value per share
8.625% Senior Notes due 2026
11.875% Senior Notes due 2027
Product and Service [Axis]
Product Sales Net [Member]
Other Revenues [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Parent [Member]
Noncontrolling Interest [Member]
Legal Entity [Axis]
Eton Pharmaceuticals, Inc. [Member]
Antidilutive Securities [Axis]
Stock Options, Unvested RSUs And Unvested PSUs [Member]
Award Type [Axis]
Restricted Stock Units (RSUs) [Member]
Investment, Name [Axis]
Melt Pharmaceuticals, Inc. [Member]
Investment Type [Axis]
Preferred Stock [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Debt Instrument [Axis]
2016 Notes [Member]
2027 Notes [Member]
Oaktree Loan [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Management Services Agreement [Member]
Series B Preferred Stock [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Capitalized Internal Use Software [Member]
Third Party Software License [Member]
Capitalized Software Development Costs [Member]
Statistical Measurement [Axis]
Minimum [Member]
Patents [Member]
Maximum [Member]
Licenses [Member]
Trademarks [Member]
New Drug Applications [Member]
Customer Relationships [Member]
Trade Names [Member]
Non-Competition Clause [Member]
State Pharmacy Licenses [Member]
Acquired NDAs [Member]
Financing Agreement [Member]
Oaktree Fund Administration LLC [Member]
Long-Term Debt, Type [Axis]
Senior Secured Term Loan [Member]
Oaktree Credit Agreement Amendment [Member]
11.875% Senior Notes Due 2027 [Member]
8.625% Senior Notes Due 2026 [Member]
Long-Lived Tangible Asset [Axis]
Office and Laboratory Space [Member]
Geographical [Axis]
Carlsbad [Member]
Ledgewood [Member]
Lease Amendment [Member]
Nashville [Member]
Nashville 1 [Member]
Nashville 2 [Member]
Share-Based Payment Arrangement, Option [Member]
Related and Nonrelated Parties [Axis]
Andrew R Boll [Member]
Mark LBaum [Member]
John Saharek [Member]
Title and Position [Axis]
Employees [Member]
Director [Member]
Plan Name [Axis]
2017 Incentive Stock and Awards Plan [Member]
Stock Option Plan [Member]
Employees and Consultant [Member]
Employees and Directors [Member]
Unvested RSU [Member]
Unvested PSU [Member]
Stock Option Plan [Member]
Exercise Price Range [Axis]
Range One [Member]
Range Two [Member]
Range Three [Member]
Range Four [Member]
Range Five [Member]
Range Six [Member]
Range Seven [Member]
Range Eight [Member]
Range Nine [Member]
Range Ten [Member]
Performance Stock Units PSU [Member]
Statement of Income Location, Balance [Axis]
Selling, General and Administrative Expenses [Member]
Research and Development Expense [Member]
Consultant [Member]
Asset Purchase, License and Related Agreements [Member]
Sales and Marketing Agreements [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
One Product Concentration Risk [Member]
Concentration Risk Benchmark [Axis]
Revenue Benchmark [Member]
Concentration Risk Type [Axis]
Product Concentration Risk [Member]
Two Product Concentration Risk [Member]
Customer [Axis]
Single Customer [Member]
Accounts Receivable [Member]
Customer Concentration Risk [Member]
Three Suppliers [Member]
Supplier Concentration Risk [Member]
Statement [Table]
Statement [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement of Financial Position [Abstract]
ASSETS
Current assets
Cash and cash equivalents
Investment in Eton Pharmaceuticals
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Total current assets
Property, plant and equipment, net
Capitalized software costs, net
Operating lease right-of-use assets, net
Intangible assets, net
Goodwill
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued expenses
Accrued rebates and copay assistance
Accrued payroll and related liabilities
Deferred revenue and customer deposits
Current portion of operating lease obligations
Total current liabilities
Operating lease obligations, net of current portion
Accrued expenses, net of current portion
Notes payable, net of unamortized debt discount
TOTAL LIABILITIES
Commitments and contingencies
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 35,380,955 and 35,168,260 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Additional paid-in capital
Accumulated deficit
TOTAL HARROW, INC. STOCKHOLDERS’ EQUITY
Noncontrolling interests
TOTAL STOCKHOLDERS’ EQUITY
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Revenues:
Total revenues
Cost of sales
Gross profit
Operating expenses:
Selling, general and administrative
Research and development
Total operating expenses
(Loss)income from operations
Other (expense) income:
Interest expense, net
Investment (loss) gain from Eton Pharmaceuticals
Loss on extinguishment of debt
Other income, net
Total other expense, net
Loss before income tax expense
Income tax benefit
Net loss
Basic net loss per share of common stock
Diluted net loss per share of common stock
Weighted average number of shares of common stock outstanding, basic
Weighted average number of shares of common stock outstanding, diluted
Balance
Balance, shares
Exercise of employee stock-based options
Exercise of employee stock-based options, shares
Vesting of RSUs
Vesting of RSUs, shares
Shares withheld related to net share settlement of equity awards
Shares withheld related to net share settlement of equity awards, shares
Stock-based compensation expense
Net loss
Balance
Balance, shares
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment and software development costs
Amortization of intangible assets
Amortization of operating lease right-of-use assets
(Recovery of) provision for credit losses
Amortization of debt issuance costs and debt discount
Investment loss (gain) from investment in Eton
Loss on extinguishment of debt
Stock-based compensation
Deferred income tax
Changes in assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Accounts payable, accrued expenses, accrued rebates and copay assistance
Accrued payroll and related liabilities
Deferred revenue and customer deposits
NET CASH USED IN OPERATING ACTIVITIES
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in patent and trademark assets
Purchase of product NDAs and related patents
Purchases of property, plant and equipment
NET CASH USED IN INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from 11.875% notes payable, net of costs
Proceeds from Oaktree Loan, net of costs
Payment of payroll taxes upon vesting of PSUs, RSUs and exercise of stock options
Proceeds from exercise of stock options
Proceeds from B. Riley senior secured note, net of costs
Repayment of B. Riley senior secured note
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES
NET CHANGE IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
CASH AND CASH EQUIVALENTS AT END OF PERIOD
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
Cash paid for interest
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Reclassification of deferred financing costs
Accrual of exit fee related to Oaktree Loan
Purchase of property, plant and equipment included in accounts payable and accrued expenses
Right-of-use assets obtained in exchange for new operating lease obligations
Income taxes owed for exercise of options
Insurance premium financed
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Revenue from Contract with Customer [Abstract]
REVENUES
Investments, Debt and Equity Securities [Abstract]
INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS
Inventory Disclosure [Abstract]
INVENTORIES
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT
Capitalized Software Costs
CAPITALIZED SOFTWARE COSTS
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Debt Disclosure [Abstract]
DEBT
Leases
LEASES
Equity [Abstract]
STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Segment Reporting [Abstract]
SEGMENTS AND CONCENTRATIONS
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Risks, Uncertainties and Liquidity
Fair Value Measurements
Basic and Diluted Net Loss per Common Share
Income Taxes
Investment in Melt Pharmaceuticals, Inc. – Related Party
Accounting Guidance Issued but Not Adopted at March 31, 2024
Reclassifications
SCHEDULE OF ESTIMATED FAIR VALUE
SCHEDULE OF BASIC NET LOSS PER SHARE OF COMMON STOCK
SCHEDULE OF INVESTMENT
SCHEDULE OF DISAGGREGATED REVENUE
SCHEDULE OF CONDENSED INCOME STATEMENT
SCHEDULE OF CONDENSED BALANCE SHEET
SCHEDULE OF INVENTORIES
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT
SCHEDULE OF CAPITALIZED SOFTWARE COSTS
SCHEDULE OF INTANGIBLE ASSETS
SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS
SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES
SCHEDULE OF LONG TERM DEBT
SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES
SCHEDULE OF FUTURE LEASE PAYMENTS UNDER OPERATING LEASES
SCHEDULE OF STOCK OPTION PLAN ACTIVITY
SCHEDULE OF FAIR VALUE ASSUMPTIONS
SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE
SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY
SCHEDULE OF PERFORMANCE STOCK UNITS ACTIVITY
SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES, DIRECTORS AND CONSULTANTS
Consolidation basis description
Platform Operator, Crypto Asset [Table]
Platform Operator, Crypto Asset [Line Items]
Carrying value
Fair value
Numerator – net loss
Schedule of Investments [Table]
Schedule of Investments [Line Items]
Cost basis
Share of Equity Method Losses
Net Carrying Value
Investment owned at fair value
Stock options, unvested RSUs, and unvested PSUs
Vested RSU
Effective income tax rate
Federal income tax rate
Unrecognized tax benefits
Investment owned balance shares
Ownership percentage
Disaggregation of Revenue [Table]
Disaggregation of Revenue [Line Items]
Contract with customer liability current
Revenues, net
Loss from operations
Current assets
Non-current assets
Total assets
Total liabilities
Total preferred stock and stockholders’ equity
Total liabilities and stockholders’ equity
Administrative fees expense
Reimbursable expenses
Repayments of related party debt
Gross proceeds from third party investors
Raw materials
Work in progress
Finished goods
Total inventories
Prepaid insurance
Prepaid computer software licenses and related expenses
Other prepaid expenses
Receivable due from Melt
Prepaid FY 2024 Prescription Drug User (“PDUFA”) fees
Deferred Oaktree Loan commitment fee
Deposits and other current assets
Total prepaid expenses and other current assets
Computer hardware
Furniture and equipment
Lab and pharmacy equipment
Leasehold improvements
Property, plant and equipment, gross
Accumulated depreciation
Property, plant and equipment, net
Depreciation and amortization expenses
Intangible Asset, Finite-Lived [Table]
Finite-Lived Intangible Assets [Line Items]
Total gross capitalized software for internal-use
Accumulated amortization
Capitalized internal-use software in process
Total capitalized software costs net
Amortization expenses
Intangible assets, Useful life
Intangible assets, Cost
Intangible assets, Accumulated amortization
Intangible assets, Disposal
Intangible assets, Net Carrying value
Useful life, description
Remainder of 2024
2025
2026
2027
2028
Thereafter
Intangible assets
Carrying value of goodwill
Accounts payable
Accrued insurance premium
Other accrued payments
Accrued interest (see Note 11)
Accrued exit fee for Oaktree Loan (see Note 11)
Total accounts payable and accrued expenses
Less: current portion
Non-current total accrued expenses
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument interest rate, during period
Accrued monthly payments
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Notes payable gross
Less: Unamortized debt issuance costs
Notes payable net
Remainder of 2024
2025
2026
2027
Total minimum payments
Less: amount representing interest payments
Notes payable, gross principal amount due
Less: unamortized debt issuance costs, net of premium
Notes payable, net of unamortized debt issuance costs
Schedule of Long-Term Debt Instruments [Table]
Debt Instrument [Line Items]
Face amount
Debt instrument, increase (decrease)
Proceeds from issuance of debt
Debt instrument interest rate effective percentage
Interest expense other than long term debt
Amortization of financing costs and discount
Interest rate
Effective interest rate
Schedule Of Future Lease Payments Under Operating Leases
Remainder of 2024
2025
2026
2027
2028
Thereafter
Total minimum lease payments
Less: amount representing interest payments
Total operating lease obligations
Less: current portion, operating lease obligations
Lease term
Area of land
Lease expiration date, description
Area of land
Weighted average discount rate percent
Lease term
Operating lease payments
Operating lease expense
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, outstanding, beginning balance
Weighted average exercise price, outstanding, beginning balance
Number of shares, options granted
Weighted average exercise price, options granted
Number of shares, options exercised
Weighted average exercise price, options exercised
Number of shares, options cancelled/forfeited
Weighted average exercise price, options cancelled/forfeited
Number of shares, outstanding, ending balance
Weighted average exercise price, outstanding, ending balance
Weighted average. remaining contractual life, options outstanding
Aggregate intrinsic value, options outstanding
Number of shares, options exercisable
Weighted average exercise price, options exercisable
Weighted average. remaining contractual life, options exercisable
Aggregate intrinsic value, options exercisable
Number of shares, options vested and expected to vest
Weighted average exercise price, options vested and expected to vest
Weighted average. remaining contractual life, options vested and expected to vest
Aggregate intrinsic value, options exercisable
Weighted-average fair value of options granted
Expected terms (in years)
Expected volatility
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Dividend yield
Share-Based Payment Arrangement, Option, Exercise Price Range [Table]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum
Range of Exercise Prices, maximum
Number of Options Outstanding
Weighted Average Remaining Contractual Life in Years
Weighted Average Exercise Price
Number Options Exercisable
Weighted Average Exercisable Exercise Price
Number of Shares, RSUs unvested, outstanding, beginning balance
Weighted average grant date fair value, beginning balance
Number of Shares, RSUs granted
Weighted average grant date fair value, RSUs granted
Number of Shares, RSUs vested
Weighted average grant date fair value, RSUs vested
Number of Shares, RSUs cancelled/forfeited
Weighted average grant date fair value, RSUs cancelled/forfeited
Number of Shares, RSUs unvested, outstanding, ending balance
Weighted average grant date fair value, ending balance
Number of Shares, PSUs granted
Number of Shares, PSUs vested
Number of Shares, PSUs cancelled/forfeited
Total
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued
Proceeds from stock option exercise
Exercise of option, shares
Exercise price, minimum
Exercise price, maximum
Number of shares granted
Shares withheld for tax withholding obligation, shares
Payroll tax obligations, value
Number of shares authorized
Common shares available for future issuances
Closing price of common stock price per share
Vesting term description
Forfeiture factor rate
Unrecognized compensation expense
Weighted-average period years
Intrinsic value of options exercised
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Royalty expenses
Upfront and milestone payments
Description for commission payments
Commission payments percentage
Commission expenses
Payment of minimum annual order amounts
Schedule of Revenue by Major Customers, by Reporting Segments [Table]
Revenue, Major Customer [Line Items]
Concentration risk percentage
Subsequent Event [Table]
Subsequent Event [Line Items]
Proceeds from issuance of common stock
Options to purchase common shares
Exercise price per share
Number of shares sold
Gross price
Trading and commissions expenses
Net proceeds from issuance of shares
Accrued rebates and copay assistance.
Purchase of product NDAS and related patents.
Proceeds from 11.875% notes payable, net of costs.
Payment of payroll taxes upon vesting of PSUs, RSUs and exercise of stock options.
Reclassification of deferred financing costs.
Accrual of exit fee related to Oaktree Loan.
Purchase of property, plant and equipment included in accounts payable and accrued expenses.
Income taxes owed for exercise of options.
Insurance premium financed.
Consolidation basis, description.
Risks Uncertainties And Liquidity [Policy Text Block]
Capitalized Software Costs [Text Block]
Capitalized Software Development Costs [Table Text Block]
Capitalized computer software internal use in process.
Capitalized Software Development Costs [Member]
Eton Pharmaceuticals, Inc. [Member]
2016 Notes [Member]
2027 Notes [Member]
Oaktree Loan [Member]
Stock Options, Unvested RSUs And Unvested PSUs [Member]
Melt Pharmaceuticals, Inc. [Member]
Other Revenues [Member]
Management Services Agreement [Member]
Receivable due from related party.
Deferred commitment fee.
Computer hardware gross.
Licenses [Member]
New Drug Applications [Member]
Non-Competition Clause [Member]
State Pharmacy Licenses [Member]
Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Accrued exit fee for note payable current and non current.
Financing Agreement [Member]
Accrued monthly payments.
Oaktree Fund Administration LLC [Member]
Senior Secured Term Loan [Member]
Oaktree Credit Agreement Amendment [Member]
11.875% Senior Notes Due 2027 [Member]
8.625% Senior Notes Due 2026 [Member]
Office and Laboratory Space [Member]
Carlsbad [Member]
Lease expiration date description.
Ledgewood [Member]
Additional area of land.
Lease Amendment [Member]
Nashville [Member]
Nashville 1 [Member]
Nashville 2 [Member]
Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Andrew R Boll [Member]
Mark LBaum [Member]
John Saharek [Member]
Employees [Member]
2017 Incentive Stock and Awards Plan [Member]
Stock Option Plan [Member]
Closing price of common stock price per share.
Stock Option Plan [Member]
Employees and Consultant [Member]
Forfeiture factor rate.
Employees and Directors [Member]
Range One [Member]
Range Two [Member]
Range Three [Member]
Range Four [Member]
Range Five [Member]
Range Six [Member]
Range Seven [Member]
Range Eight [Member]
Range Nine [Member]
Range Ten [Member]
Schedule Of Share Based Compensation Performance Stock Units Award Activity [Table Text Block]
Performance Stock Units PSU [Member]
Unvested PSU [Member]
Asset Purchase, License and Related Agreements [Member]
Description for commission payments.
Sales and Marketing Agreements [Member]
Commission payments, percentage.
Two Product Concentration Risk [Member]
One Product Concentration Risk [Member]
Single Customer [Member]
Three Suppliers [Member]
Unvested RSU [Member]
Upfront and milestone payments.
Product Sales Net [Member]
Capitalized Internal Use Software [Member]
Third Party Software License [Member]
Acquired NDAs [Member]
Consultant [Member]
Stock Option Plan [Member] [Default Label]
Assets, Current
Liabilities, Current
Equity, Including Portion Attributable to Noncontrolling Interest
Cost of Goods and Services Sold
Gross Profit
Operating Expenses
Interest Expense, Operating and Nonoperating
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Income Tax Expense (Benefit)
Shares, Outstanding
Stock Issued During Period, Shares, Other
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Employee Related Liabilities
Increase (Decrease) in Contract with Customer, Liability
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Intangible Assets
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Payment of payroll taxes upon vesting of PSUs, RSUs and exercise of stock options
Repayments of Senior Debt
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Equity Method Investment, Aggregate Cost
Property, Plant and Equipment, Gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Capitalized Computer Software, Accumulated Amortization
Finite-Lived Intangible Assets, Net
Accounts Payable and Accrued Liabilities
Long-Term Debt, Maturity, Remainder of Fiscal Year
Long-Term Debt, Maturity, Year One
Long-Term Debt, Maturity, Year Two
Long-Term Debt, Maturity, Year Three
Long-Term Debt
Interest Payable, Current
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Lessee, Operating Lease, Liability, to be Paid, Year One
Lessee, Operating Lease, Liability, to be Paid, Year Two
Lessee, Operating Lease, Liability, to be Paid, Year Three
Lessee, Operating Lease, Liability, to be Paid, Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Additional square footage
Operating Lease, Weighted Average Remaining Lease Term
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period